Patents Examined by Matthew Latimer
  • Patent number: 5962311
    Abstract: The present invention provides a short-shafted adenoviral fiber, a recombinant adenovirus comprising a short-shafted fiber, a vector comprising a short-shafted adenoviral fiber gene, and a method of targeting attachment of a short-shafted recombinant adenovirus to a cell so as to effect entry of the short-shafted recombinant adenovirus into the cell.
    Type: Grant
    Filed: August 21, 1996
    Date of Patent: October 5, 1999
    Assignee: GenVec, Inc.
    Inventors: Thomas J. Wickham, Petrus W. Roelvink, Imre Kovesdi
  • Patent number: 5922323
    Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 13, 1999
    Assignee: Connaught Laboratories Limited
    Inventors: Sheena Loosmore, Robin Harkness, Anthony Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew Murdin, Michel Klein
  • Patent number: 5849891
    Abstract: A satellite RNA was found to be naturally associated with bamboo mosaic virus (BaMV-V) isolated from infected Bambusa vulgaris McClure. Nucleotide sequence revealed that this satellite RNA genome contains 836 nucleotides and encodes a 20 kDa protein. Infectious transcripts have been generated from full length cDNA downstream T7 RNA polymerase promoter. Precise replacement of open reading frame (ORF) of cDNA of satellite RNA with sequence encoding bacterial CAT (chloramphenicol acetyltransferase) resulted in high level expression of CAT in infected dicotyledon plants, Chenopodium quinoa and tobacco (Nicotiana benthamiana) in the presence of baMV genomic RNA. Thus, this satellite system is potentially useful as a satellite-based plant expression vector.
    Type: Grant
    Filed: July 28, 1995
    Date of Patent: December 15, 1998
    Assignee: National Science Council
    Inventors: Na-Sheng Lin, Yau-Heiu Hsu
  • Patent number: 5847097
    Abstract: Methods of designing or modifying protein structure at the protein or genetic level to produce specified amino-termini in vivo or in vitro are described. The methods can be used to alter the metabolic stability and other properties of the protein or, alternatively, to artificially generate authentic amino-termini in proteins produced through artificial means. The methods are based upon the introduction of the use of artificial ubiquitin-protein fusions, and the discovery that the in vivo half-life of a protein is a function of the amino-terminal amino acid of the protein.
    Type: Grant
    Filed: December 14, 1995
    Date of Patent: December 8, 1998
    Assignee: Massachusetts Institute of Technology
    Inventors: Andreas Bachmair, Daniel Finley, Alexander Varshavsky
  • Patent number: 5827738
    Abstract: A sustainable cell line of a Marek's disease herpesvirus (MDV) infected chicken cell line derived from chick embryo cells which are chicken helper factor (Chf) negative and which have been treated with N-methyl-N-nitro-N-nitrosoguansidine (MNNG) and then converted with the MDV which is able to infect avians in vivo. The cell line is useful for vaccine production and for determining the characteristics of the MDV under various conditions.
    Type: Grant
    Filed: October 27, 1995
    Date of Patent: October 27, 1998
    Assignee: Board of Trustees operating Michigan State University
    Inventors: Paul M. Coussens, Amin Abujoub
  • Patent number: 5824552
    Abstract: A method is disclosed for culturing animal cells in a medium characterized n that said medium contains a compound represented by the general formula ##STR1## wherein, R denotes COOM or CHO, herein M denotes hydrogen, an alkali metal or a C.sub.1 to C.sub.3 alkyl group, and n is an integer of 1 to 3.According to the present method, proliferation of animal cells can be enhanced with good reproducibility.
    Type: Grant
    Filed: August 15, 1996
    Date of Patent: October 20, 1998
    Assignees: Teijin Limited, Juridical Foundation The Chemo-Sero-Therapeutic Research Institute
    Inventors: Yoshiharu Takazawa, Takami Arai, Masamichi Motoki, Kenji Nagura, Seiichi Yokoyama, Yoshinobu Miyatsu, Hiroshi Mizokami
  • Patent number: 5821071
    Abstract: The present invention relates, in general, to methods of stimulating phagocytosis and thereby combating infection and/or modulating immune complex disease, in particular, to methods of modulating the number and type of Fc receptors present on cells that normally possess such receptors, including monocytes and macrophages, as well as on cells that normally do not possess Fc receptors, such as fibroblasts, and to compounds and compositions suitable for use in such methods.
    Type: Grant
    Filed: September 30, 1994
    Date of Patent: October 13, 1998
    Assignee: University of Pennsylvania
    Inventors: Alan D. Schreiber, Jong-Gu Park
  • Patent number: 5786463
    Abstract: The invention provides isolated nucleic acid compounds encoding a multiple drug resistance protein of Cryptococcus neoformans. Vectors and transformed host cells comprising the multiple drug resistance-encoding DNA of Cryptococcus neoformans CneMDR1 are also provided. The invention further provides assays which utilize these transformed host cells.
    Type: Grant
    Filed: March 8, 1996
    Date of Patent: July 28, 1998
    Assignee: Eli Lilly and Company
    Inventors: Robert Brown Peery, Paul Luther Skatrud, Susan Jane Thornewell
  • Patent number: 5783442
    Abstract: A cloning vector plasmid suitable for preparing cDNA banks is disclosed.
    Type: Grant
    Filed: September 9, 1996
    Date of Patent: July 21, 1998
    Assignee: Sagami Chemical Research Center
    Inventors: Seishi Kato, Takashi Aoki, Yuri Umezawa
  • Patent number: 5780258
    Abstract: The invention provides methods and compositions for screening for pharmacological agents which regulate satiety, fat metabolism and/or the type II diabetes mellitus in mammals, and in particular, agents active at regulating the level of ob gene expression. An exemplary assay involves (a) contacting a mammalian adipocyte comprising a mutant of a native ob allele encoding a reporter of ob gene expression, wherein the expression of the reporter is under the control of the gene expression regulatory sequences of the native ob allele, with a candidate agent under conditions whereby but for the presence of the agent, the reporter is expressed at a first expression level; and, (b) measuring the expression of the reporter to obtain a second expression level, wherein a difference between the first and second expression levels indicates that the candidate agent modulates ob gene expression.
    Type: Grant
    Filed: September 4, 1996
    Date of Patent: July 14, 1998
    Assignee: Tularik, Inc
    Inventors: Fabienne Charles de la Brousse, Jin-long Chen
  • Patent number: 5736529
    Abstract: The present invention is directed to methods for reducing the degree of neural degeneration in a mammal due to acute neural trauma by the administration of a NAD-related compound and for kits useful in the method. NAD-related compounds include quinolinic acid; quinolinic acid ribonucleotide; nicotinamide; nicotinic acid; nicotinic acid ribonucleotide; nicotinic acid ribonucleotide, reduced form; nicotinamide ribonucleotide; nicotinamide ribonucleotide, reduced form; nicotinic acid adenine dinucleotide; nicotinic acid adenine dinucleotide, reduced form; nicotinamide adenine dinucleotide (NAD); nicotinamide adenine dinucleotide phosphate (NADP); nicotinamide adenine dinucleotide, reduced form (NADH); and nicotinamide adenine dinucleotide phosphate, reduced form (NADPH) and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: March 22, 1996
    Date of Patent: April 7, 1998
    Assignee: Neurocal International Inc.
    Inventors: James David Adams, Lori Kathleen Klaidman, Suman Kumar Mukherjee
  • Patent number: 5736157
    Abstract: A method of regulating cholesterol related genes, enzymes and other compounds, pharmaceutical compositions and a kit related thereto are provided. Exemplary genes that are regulated include a gene for an LDL receptor, a gene for HMG-CoA reductase, a gene for cholesterol 7-alpha-hydroxylase, and a gene regulating a function involved in cholesterol homeostasis. The method comprises the step of parentorally administering a therapeutically effective amount of a lipid acceptor. The lipid acceptor in one variant includes a multiplicity of large liposomes comprised of phospholipids substantially free of sterol during a treatment period. The method includes the steps of periodically assaying plasma LDL concentrations with an assay during a period of time to assess said plasma LDL and to obtain an LDL profile, and adjusting the parenteral administration in response to the LDL profile.
    Type: Grant
    Filed: October 11, 1996
    Date of Patent: April 7, 1998
    Inventor: Kevin Jon Williams
  • Patent number: 5731190
    Abstract: A recombinant adenovirus comprising a chimeric penton base protein, which includes a nonpenton base sequence, and a therapeutic gene, a method of gene therapy involving the use of such adenovirus, and adenoviral transfer vectors for the generation of such recombinant adenovirus are provided.
    Type: Grant
    Filed: September 6, 1996
    Date of Patent: March 24, 1998
    Assignee: GenVec, Inc.
    Inventors: Thomas J. Wickham, Imre Kovesdi, Douglas E. Brough, Duncan L. McVey, Joseph T. Bruder
  • Patent number: 5731196
    Abstract: A vector capable of integrating into the chromosome of Salmonella including a first DNA sequence encoding a heterologous protein, a second DNA sequence encoding a marker, and a third DNA sequence encoding a phoP regulatory region regulated gene product necessary for virulence, the third DNA sequence being mutationally inactivated
    Type: Grant
    Filed: October 6, 1995
    Date of Patent: March 24, 1998
    Assignees: The General Hospital Corporation, President and Fellows of Harvard College
    Inventors: Samuel I. Miller, III, John J. Mekalanos
  • Patent number: 5708149
    Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 13, 1998
    Assignee: Connaught Laboratories Limited
    Inventors: Sheena Loosmore, Robin Harkness, Anthony Schryvers, Pele Chong, Scott Gray-Owen, Yan-Ping Yang, Andrew Murdin, Michel Klein
  • Patent number: 5707862
    Abstract: A shuttle vector containing an yeast gene and an E. coli gene and carrying the expression control region of acid phosphatase gene of yeast, which can be recombined with various genes under control of the phosphatase promoter, to give various recombinant plasmids. The shuttle vector is useful in genetic engineering industries.
    Type: Grant
    Filed: December 5, 1990
    Date of Patent: January 13, 1998
    Assignees: Juridical Foundation The Chemi-Sero-Therapeutic Research Institute, Science and Technology Agency, Minister's Secretariat Director of Finance Division
    Inventors: Atsushi Miyanohara, Akio Toh-e, Kenichi Matsubara
  • Patent number: 5698433
    Abstract: A method of producing an influenza virus and vaccines derived from the virus utilizes cultured vertebrate biomass aggregates comprising a plurality of cell types derived from a plurality of vertebrate tissues and is particularly suitable for use with chicken embryo cultures. The method both eliminates the necessity to use costly methods requiring whole chicken embryos and provides proteases suitable for the activation of a wide variety of viruses. After infecting the cells of the culture with an influenza virus, which is preferably modified to create a cleavage site in the hemagglutinin of the virus, a substance such as a protease is introduced that cleaves the hemagglutinin. The culture then is incubated under conditions that permit growth of the virus.
    Type: Grant
    Filed: July 22, 1996
    Date of Patent: December 16, 1997
    Assignee: Immuno AG
    Inventors: Otfried Kistner, Noel Barrett, Wolfgang Mundt, Friedrich Dorner
  • Patent number: 5677420
    Abstract: The present invention relates to phospholipase C-inhibiting peptides which are represented by formula (I): ##STR1## wherein n represents 0 or 1; each J.sup.1 and J.sup.2 is a hydrogen atom, or J.sup.1 and J.sup.2 are combined together to form a single bond; W represents a hydrogen atom, a substituted or unsubstituted alkanoyl group, a substituted or unsubstituted aroyl group or coumaryl group; X represents a single bond, -Leu-, or -Ser-Leu-Val-Glu-Leu-Val-Ser-Tyr-Tyr-Glu-Lys-His-Ala-Leu- (wherein at least one amino acid residue may be deleted, inserted or substituted); Y represents a single bond or -Pro-Val-; R.sup.1 represents a hydrogen atom, a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group; and R.sup.2 represents a substituted or unsubstituted alkyl group or a substituted or unsubstituted aryl group.
    Type: Grant
    Filed: November 8, 1996
    Date of Patent: October 14, 1997
    Assignee: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Motoo Yamasaki, Genkichi Ishikawa, Yoshimi Honma
  • Patent number: 5663313
    Abstract: The present invention provides nucleic acid and amino acid sequences that identify and encode a novel human map kinase homolog (SMAP) expressed in cells of the human stomach. The present invention also provides for PCR oligomers or hybridization probes for the detection of nucleotide sequences encoding SMAP or SMAP-like molecules, antisense molecules to the nucleotide sequences which encode SMAP, diagnostic tests based on SMAP encoding nucleic acid molecules, genetically engineered expression vectors and host cells for the production of purified SMAP, antibodies capable of binding specifically to SMAP, and agonists and inhibitors with specific binding activity for the polypeptide SMAP.
    Type: Grant
    Filed: June 28, 1996
    Date of Patent: September 2, 1997
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Janice Au-Young, Karl J. Guegler, Craig G. Wilde
  • Patent number: 5618723
    Abstract: A process of identifying and disrupting bacterial DNA sequences that contribute to the evolution of new lytic bacteriophages is described. Vectors and recombinant bacteria for use in producing fermentative starter cultures and culture resistant to the appearance of new phages, and methods of producing such vectors and recombinant bacteria, are described.
    Type: Grant
    Filed: April 18, 1995
    Date of Patent: April 8, 1997
    Assignee: North Carolina State University
    Inventors: Todd R. Klaenhammer, Sylvain Moineau